Search Results for "infusers"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for infusers. Results 391 to 400 of 410 total matches.

Romosozumab (Evenity) for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
myeloma, and bone metastases from solid tumors. 9. Cost of one 5 mg/100 mL infusion bottle. 10 ...
The FDA has approved romosozumab-aqqg (Evenity – Amgen), a sclerostin inhibitor, for once-monthly subcutaneous (SC) treatment of osteoporosis in postmenopausal women who are at high risk for fracture (history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or cannot tolerate other drugs for this indication. Romosozumab is the first sclerostin inhibitor to be approved in the US and the third drug for treatment of postmenopausal osteoporosis that stimulates bone formation; the parathyroid hormone (PTH) receptor agonists abaloparatide (Tymlos) and...
Med Lett Drugs Ther. 2019 Jun 3;61(1573):83-6 |  Show IntroductionHide Introduction

IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
is recommended. Amisulpride should be infused over 1-2 minutes. The drug is subject to photodegradation ...
The FDA has approved IV amisulpride (Barhemsys – Acacia), a selective dopamine-2 and -3 (D2/D3) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults. It is the first antiemetic to be approved for rescue treatment of PONV in patients who have symptoms despite receiving antiemetic prophylaxis. Oral formulations of amisulpride are available in Europe for treatment of schizophrenia and acute psychotic episodes.
Med Lett Drugs Ther. 2020 Dec 28;62(1614):205-8 |  Show IntroductionHide Introduction

Choice of Cephalosporin

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 1990  (Issue 832)
include thrombophlebitis from intravenous (IV) infusions, pain at intramuscular (IM) injection sites ...
Since the last Medical Letter review of cephalosporin antibiotics (volume 25, page 57, 1983), many new cephalosporins have become available in the USA.
Med Lett Drugs Ther. 1990 Nov 30;32(832):107-10 |  Show IntroductionHide Introduction

Prevention and Treatment of Injury from Chemical Warfare Agents

   
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002  (Issue 1121)
at hourly intervals, if necessary, or continuously at 500 mg/hour by IV infusion. Diazepam − Early ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Med Lett Drugs Ther. 2002 Jan 7;44(1121):1-4 |  Show IntroductionHide Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
neuralgia, and intractable neuropathic pain such as poststroke pain and spinal cord injury.40 IV infusions ...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 |  Show IntroductionHide Introduction

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
caused by UFH, IV infusion of protamine can be used to reverse the anticoagulant effect. IV protamine ...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 |  Show IntroductionHide Introduction

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
mg/dL) were randomized to receive IV infusions of evinacumab 15 mg/kg or placebo every 4 weeks ...
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force were last published in 2019.
Med Lett Drugs Ther. 2022 Sep 19;64(1659):145-52 |  Show IntroductionHide Introduction

Antiviral Drugs

   
Treatment Guidelines from The Medical Letter • Mar 01, 2013  (Issue 127)
127) • March 2013 phlebitis and inflammation at the site of infusion and reversible renal ...
The drugs of choice for treatment of viral infections (other than HIV) and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed elsewhere.
Treat Guidel Med Lett. 2013 Mar;11(127):19-30 |  Show IntroductionHide Introduction

Intravenous Immunoglobulin (IVIG)

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006  (Issue 1249)
Letter. ADVERSE EFFECTS — Acute infusion reactions can include headache, fever, chills, myalgia, nausea ...
Intravenous immunoglobulin (IVIG) has 6 FDA approved indications and is prescribed off-label for many others. How many of these uses are justified is controversial.
Med Lett Drugs Ther. 2006 Dec 4;48(1249):101-2 |  Show IntroductionHide Introduction

Cannabis and Cannabinoids

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
. Sources of unintentional exposure included cannabis resin (hashish), cannabis joints, cannabis-infused ...
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):179-82 |  Show IntroductionHide Introduction